Таркоцимаб

Rec. INN (наименование, зарегистрированное ВОЗ)

2408661-40-3

immunoglobulin G1-kappa, anti-[Homo sapiens VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)], humanized monoclonal antibody;
gamma1 heavy chain humanized (1-453) [VH (Homo sapiens IGHV3-30*02 (75.8%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, G1v14 CH2 A1.3, A1.2 (CH1 R120>K (220) (124-221), hinge 1-15 (222-236), CH2 L1.3>A (240), L1.2>A (241), G1>A (243) (237-346), CH3 E12 (362), M14 (364), L123>C (449) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-16*01 (87.4%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (232-232'':235-235'')-bisdisulfide, produced in Chinese hamster ovary (CHO)-K1SV cell line lacking the glutamine synthetase gene (GS-KO), glycoform alfa

Поделиться этой страницей